Literature DB >> 19451447

Improvements in survival after follicular lymphoma by race/ethnicity and socioeconomic status: a population-based study.

Theresa H M Keegan1, Laura A McClure, James M Foran, Christina A Clarke.   

Abstract

PURPOSE: A recent report suggested improvements in survival after follicular lymphoma (FL), but not for all racial/ethnic groups. To better understand the reasons for these FL survival differences, we examined the joint influences of diagnostic period, race/ethnicity, and neighborhood socioeconomic status (SES) on survival in a large population-based case series.
METHODS: All patients (n = 15,937) diagnosed with FL between 1988 and 2005 in California were observed for vital status through November 2007. Overall and FL-specific survival were analyzed with Kaplan-Meier and Cox proportional hazards regression. Neighborhood SES was assigned from United States Census data using residence at diagnosis.
RESULTS: Overall and FL-specific survival improved 22% and 37%, respectively, from 1988 to 1997 to 1998 to 2005, and were observed in all racial/ethnic groups. Asian/Pacific Islanders had better survival than non-Hispanic white, Hispanic, and black patients who had similar outcomes. Lower neighborhood SES was associated with worse survival in patients across all stages of disease (P for trend < .01). Patients with the lowest SES quintile had a 49% increased risk of death from all causes (hazard ratio [HR] = 1.49, 95% CI, 1.30 to 1.72) and 31% increased risk of death from FL (HR = 1.31; 95% CI, 1.06 to 1.60) than patients with the highest SES.
CONCLUSION: Evolving therapies have likely led to improvements in survival after FL. Although improvements have occurred within all racial/ethnic groups, lower neighborhood SES was significantly associated with substantially poorer survival.

Entities:  

Mesh:

Year:  2009        PMID: 19451447      PMCID: PMC2702236          DOI: 10.1200/JCO.2008.18.8052

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  39 in total

1.  Associations between community income and cancer survival in Ontario, Canada, and the United States.

Authors:  C Boyd; J Y Zhang-Salomons; P A Groome; W J Mackillop
Journal:  J Clin Oncol       Date:  1999-07       Impact factor: 44.544

Review 2.  Multilevel analyses of neighbourhood socioeconomic context and health outcomes: a critical review.

Authors:  K E Pickett; M Pearl
Journal:  J Epidemiol Community Health       Date:  2001-02       Impact factor: 3.710

3.  Socioeconomic status and breast cancer incidence in California for different race/ethnic groups.

Authors:  K Yost; C Perkins; R Cohen; C Morris; W Wright
Journal:  Cancer Causes Control       Date:  2001-10       Impact factor: 2.506

Review 4.  Follicular lymphoma: have we made any progress?

Authors:  S J Horning
Journal:  Ann Oncol       Date:  2000       Impact factor: 32.976

5.  Ongoing improvement in outcomes for patients diagnosed as having Non-Hodgkin lymphoma from the 1990s to the early 21st century.

Authors:  Dianne Pulte; Adam Gondos; Hermann Brenner
Journal:  Arch Intern Med       Date:  2008-03-10

6.  Non-Hodgkin's lymphoma in the Netherlands: results from a population-based registry.

Authors:  A D G Krol; S le Cessie; S Snijder; J C Kluin-Nelemans; Ph M Kluin; E M Noordijk
Journal:  Leuk Lymphoma       Date:  2003-03

7.  Position paper on the therapeutic use of rituximab in CD20-positive diffuse large B-cell non-Hodgkin's lymphoma.

Authors:  Ruth Pettengell; David Linch
Journal:  Br J Haematol       Date:  2003-04       Impact factor: 6.998

8.  Non-Hodgkin's lymphoma: an analysis of the Metropolitan Detroit SEER database.

Authors:  M L Varterasian; J J Graff; R K Severson; L Weiss; A M al-Katib; G P Kalemkerian
Journal:  Cancer Invest       Date:  2000       Impact factor: 2.176

Review 9.  Staging and evaluation of the patient with lymphoma.

Authors:  Bruce D Cheson
Journal:  Hematol Oncol Clin North Am       Date:  2008-10       Impact factor: 3.722

10.  State-specific prevalence of selected chronic disease-related characteristics--Behavioral Risk Factor Surveillance System, 2001.

Authors:  Indu B Ahluwalia; Karin A Mack; Wilmon Murphy; Ali H Mokdad; Virginia S Bales
Journal:  MMWR Surveill Summ       Date:  2003-08-22
View more
  16 in total

1.  Cohort Profile: The Lymphoma Specialized Program of Research Excellence (SPORE) Molecular Epidemiology Resource (MER) Cohort Study.

Authors:  James R Cerhan; Brian K Link; Thomas M Habermann; Matthew J Maurer; Andrew L Feldman; Sergei I Syrbu; Carrie A Thompson; Umar Farooq; Anne J Novak; Susan L Slager; Cristine Allmer; Julianne J Lunde; William R Macon; David J Inwards; Patrick B Johnston; Ivana N M Micallef; Grzegorz S Nowakowski; Stephen M Ansell; Neil E Kay; George J Weiner; Thomas E Witzig
Journal:  Int J Epidemiol       Date:  2017-12-01       Impact factor: 7.196

2.  Stage-specific trends in primary therapy and survival in follicular lymphoma: a nationwide population-based analysis in the Netherlands, 1989-2016.

Authors:  Manette A W Dinnessen; Marjolein W M van der Poel; Sanne H Tonino; Otto Visser; Nicole M A Blijlevens; Daphne de Jong; King H Lam; Marie José Kersten; Pieternella J Lugtenburg; Avinash G Dinmohamed
Journal:  Leukemia       Date:  2020-10-12       Impact factor: 11.528

3.  The association of education level on outcome after distal radius fracture.

Authors:  Nader Paksima; Brian Pahk; Santiago Romo; Kenneth A Egol
Journal:  Hand (N Y)       Date:  2014-03

4.  Early event status informs subsequent outcome in newly diagnosed follicular lymphoma.

Authors:  Matthew J Maurer; Emmanuel Bachy; Hervé Ghesquières; Stephen M Ansell; Grzegorz S Nowakowski; Carrie A Thompson; David J Inwards; Cristine Allmer; Catherine Chassagne-Clément; Emmanuelle Nicolas-Virelizier; Catherine Sebban; Laure Lebras; Clementine Sarkozy; William R Macon; Andrew L Feldman; Sergei I Syrbu; Alexandra Traverse-Glehan; Bertrand Coiffier; Susan L Slager; George J Weiner; Thomas E Witzig; Thomas M Habermann; Gilles Salles; James R Cerhan; Brian K Link
Journal:  Am J Hematol       Date:  2016-09-03       Impact factor: 10.047

5.  Long-term survey of survival time, histological transformation, and secondary malignancies in Japanese patients with advanced-stage follicular lymphoma in the rituximab era: Hokkaido Hematology Study Group.

Authors:  Yasuo Hirayama; Kunihiko Ishitani; Shuithi Ota; Mitsutoshi Kurosawa; Takeshi Kondo; Rishu Takimoto; Akio Mori; Hajime Sakai; Yoshihiro Torimoto; Satoshi Yamamoto; Kazuya Sato; Hiroshi Iwasaki; Kyuhei Kohda; Tadao Ishida; Yasuhiro Kakinoki; Takashi Fukuhara; Junji Kato
Journal:  Int J Hematol       Date:  2014-07-23       Impact factor: 2.490

6.  Disparities in survival by insurance status in follicular lymphoma.

Authors:  Jordan S Goldstein; Loretta J Nastoupil; Xuesong Han; Ahmedin Jemal; Elizabeth Ward; Christopher R Flowers
Journal:  Blood       Date:  2018-07-24       Impact factor: 22.113

7.  Socioeconomic Impacts on Survival Differ by Race/Ethnicity among Adolescents and Young Adults with Non-Hodgkin's Lymphoma.

Authors:  Erin E Kent; Rebecca A Morris; Joan A Largent; Argyrios Ziogas; Leonard S Sender; Hoda Anton-Culver
Journal:  J Cancer Epidemiol       Date:  2010-06-22

8.  Bendamustine: safety and efficacy in the management of indolent non-hodgkins lymphoma.

Authors:  Nishant Tageja
Journal:  Clin Med Insights Oncol       Date:  2011-05-18

9.  Socioeconomic position, treatment, and survival of non-Hodgkin lymphoma in Denmark--a nationwide study.

Authors:  B L Frederiksen; S O Dalton; M Osler; M Steding-Jessen; P de Nully Brown
Journal:  Br J Cancer       Date:  2012-02-07       Impact factor: 7.640

10.  Socioeconomic disparities in mortality after diffuse large B-cell lymphoma in the modern treatment era.

Authors:  Li Tao; James M Foran; Christina A Clarke; Scarlett L Gomez; Theresa H M Keegan
Journal:  Blood       Date:  2014-04-04       Impact factor: 25.476

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.